FirsthandHealth
medRxiv PreprintsInternational16 November 2026

Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOO
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.